HSCS Stock Forecast: HeartSciences, Inc. Price Predictions for 2026-2027
The median 12-month analyst price target for HeartSciences, Inc. is $12. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 43 of 100 as at 21 Nov 2026 — in the lower half.
One number for the whole business
Consensus tells you what everyone already believes. The model scores HeartSciences, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Accruals (92): Reported profit is backed by cash, and the company is not expanding recklessly.
Issuance (3): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
HSCS stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on HSCS, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 24 Mar 2026 | Ascendiant Capital | Maintains | Buy | $9.20 → $8.00 |
| 22 Dec 2025 | Ascendiant Capital | Maintains | Buy | — |
| 1 Oct 2025 | Ascendiant Capital | Maintains | Buy | — |
| 18 Mar 2025 | Ascendiant Capital | Maintains | Buy | — |
| 18 Dec 2024 | Maxim Group | Reiterates | Buy | — |
| 23 Sept 2024 | Ascendiant Capital | Reiterates | Buy | — |
| 30 Jan 2023 | Ascendiant Capital | Initiates | Buy | — |
| 19 Dec 2022 | Maxim Group | Maintains | Buy | — |
| 9 Nov 2022 | Maxim Group | Initiates | Buy | — |
| 8 Aug 2022 | Benchmark | Initiates | Speculative Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for HSCS.
This page is one stock. Monday covers all of them.
HSCS appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
HSCS vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, HeartSciences, Inc. returned −39.2% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
HSCS analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- 2270.4×
- Price / book
- 61.4×
- EV / EBITDA
- —
Cheaper than 1% of US stocks
Cheaper than 1% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
- Return on equity
- −1851.9%
- Return on assets
- −116.4%
- Dividend yield
- —
Higher than 1% of US stocks
Higher than 2% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
HeartSciences, Inc. has a market value of $9.0M and an enterprise value of $12.7M.
Revenue in the twelve months to 30 Apr 2026: $4K. The latest quarter shrank 100.0% year on year.
Net income over the same four quarters: −$9.1M, a −211666.5% net margin.
Free cash flow in the twelve months to 30 Apr 2026: −$7.5M.
HeartSciences, Inc. employs 14 people — $308.5 of revenue per employee.
Data provided by Twelve Data
HSCS and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at HSCS’s peer groups, ranked by the model: healthcare stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own HeartSciences, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about HSCS
What is the HSCS stock price forecast for 2026-2027?
The median 12-month analyst price target for HeartSciences, Inc. is $12. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is HSCS stock a buy right now?
Of the 1 analyst covering HeartSciences, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks HeartSciences, Inc. 43 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank HSCS?
As at 21 Nov 2026, HeartSciences, Inc. ranks 43 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Accruals (92 of 100).
Will HSCS stock go up?
No one can know that. What the data says: the median 12-month target from 1 analyst is $12, and Ticker Nerd's factor model ranks HeartSciences, Inc. 43 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the HSCS stock forecast for 2030?
No analyst covering HeartSciences, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for HSCS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $12 to $12 over the next 12 months.
How has HSCS stock performed over the past year?
HeartSciences, Inc. returned -39.2% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does HeartSciences, Inc. do?
HeartSciences Inc. is a medical technology company focused on artificial intelligence-enhanced electrocardiography. The company develops AI-ECG solutions designed to improve the clinical usefulness of standard ECG testing by helping detect cardiac dysfunction and related heart conditions earlier in care pathways.
About HeartSciences, Inc.
HeartSciences Inc. is a medical technology company focused on artificial intelligence-enhanced electrocardiography. The company develops AI-ECG solutions designed to improve the clinical usefulness of standard ECG testing by helping detect cardiac dysfunction and related heart conditions earlier in care pathways. Its current product set includes the MyoVista wavECG device, a resting 12-lead ECG that combines conventional rhythm and diagnostic information in a single test, and MyoVista Insights, a cloud-native ECG management platform that is designed to work across different device and vendor environments. HeartSciences serves healthcare settings where rapid cardiac screening and interpretation are important, including frontline and point-of-care environments. Founded in 2007 and headquartered in Southlake, Texas, the company positions itself within the healthcare information technology and medical devices market, with a focus on practical ECG enhancement rather than replacing existing clinical workflows.
CEO Mr. Andrew Simpson · 14 employees · United States · https://heartsciences.com